Massimo Aglietta

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3475557/publications.pdf

Version: 2024-02-01

354 papers	18,559 citations	17405 63 h-index	16127 124 g-index
356 all docs	356 docs citations	356 times ranked	21894 citing authors

#	Article	IF	Citations
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	0.6	6
2	Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. Journal of Chemotherapy, 2022, 34, 123-132.	0.7	1
3	First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. Journal of Clinical Oncology, 2022, 40, 161-170.	0.8	283
4	HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis. Transplantology, 2022, 3, 51-67.	0.3	0
5	Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma. Journal of Clinical Medicine, 2022, 11, 828.	1.0	10
6	Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2022, 12, 771418.	1.3	4
7	Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study. ESMO Open, 2022, 7, 100431.	2.0	1
8	NivolumabÂplus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology, 2022, 33, 1052-1060.	0.6	81
9	Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update.. Journal of Clinical Oncology, 2021, 39, 58-58.	0.8	19
10	Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective. Cells, 2021, 10, 543.	1.8	14
11	Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy. Vaccines, 2021, 9, 235.	2.1	3
12	Post-Transplant Cyclophosphamide and Tacrolimusâ€"Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173.	1.0	10
13	A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient. Cancers, 2021, 13, 2051.	1.7	8
14	Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. European Journal of Cancer, 2021, 149, 153-164.	1.3	79
15	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). Cancers, 2021, 13, 2466.	1.7	7
16	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
17	Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. Cancers, 2021, 13, 2302.	1.7	2
18	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	1.7	31

#	Article	IF	Citations
19	High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients. ESMO Open, 2021, 6, 100133.	2.0	12
20	Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. Gynecologic Oncology, 2021, 162, 80-87.	0.6	5
21	A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy. Acta OncolÃ³gica, 2021, 60, 1317-1324.	0.8	2
22	Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients. BMC Cancer, 2021, 21, 865.	1.1	4
23	Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. European Journal of Cancer, 2021, 155, 56-63.	1.3	8
24	EphA2 Expression in Bone Sarcomas: Bioinformatic Analyses and Preclinical Characterization in Patient-Derived Models of Osteosarcoma, Ewingâ€™s Sarcoma and Chondrosarcoma. Cells, 2021, 10, 2893.	1.8	7
25	Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy). Targeted Oncology, 2021, 16, 789-799.	1.7	5
26	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomasâ€"A Preclinical and Translational Study. Cancers, 2021, 13, 6295.	1.7	0
27	Safe Use of Carfilzomib in a Patient with Multiple Myeloma and Intermittent Type 1 Brugada ECG Pattern: A Case Report. Acta Haematologica, 2020, 143, 481-485.	0.7	0
28	Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018. Lung Cancer, 2020, 139, 47-54.	0.9	28
29	Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II). Melanoma Research, 2020, 30, 261-267.	0.6	27
30	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	1.9	42
31	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naÃ¯ve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096872.	1.4	6
32	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. Clinical Cancer Research, 2020, 26, 6321-6334.	3.2	24
33	Evolution of the Experimental Models of Cholangiocarcinoma. Cancers, 2020, 12, 2308.	1.7	76
34	Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers, 2020, 12, 3256.	1.7	8
35	COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. JCO Oncology Practice, 2020, 16, 295-298.	1.4	35
36	Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. Journal of Ovarian Research, 2020, 13, 53.	1.3	6

#	Article	IF	Citations
37	Pazopanib and Trametinib as a Synergistic Strategy against Osteosarcoma: Preclinical Activity and Molecular Insights. Cancers, 2020, 12, 1519.	1.7	15
38	Melanoma Brain Metastases in the Era of Target Therapies: An Overview. Cancers, 2020, 12, 1640.	1.7	29
39	Khorana score and thromboembolic risk in stage IIâ€“III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989985.	1.4	6
40	Response to eribulin in a patient with metastatic uterine leiomyosarcoma: a case report. Future Oncology, 2020, 16, 15-19.	1.1	2
41	Quality of life assessment and reporting in colorectal cancer: A systematic review of phase III trials published between 2012 and 2018. Critical Reviews in Oncology/Hematology, 2020, 146, 102877.	2.0	14
42	Preclinical immunotherapy with Cytokine-Induced Killer lymphocytes against epithelial ovarian cancer. Scientific Reports, 2020, 10, 6478.	1.6	8
43	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer, 2019, 19, 794.	1.1	20
44	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. Clinical Genitourinary Cancer, 2019, 17, 332-347.e2.	0.9	9
45	Is There a Standard Adjuvant Therapy for Resected Pancreatic Cancer?. Cancers, 2019, 11, 1547.	1.7	10
46	Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives. Expert Opinion on Pharmacotherapy, 2019, 20, 2121-2137.	0.9	7
47	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18, e394-e401.	1.0	13
48	CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. International Journal of Molecular Sciences, 2019, 20, 2839.	1.8	34
49	Preventing Venous Thromboembolism in Patients with Cancer. New England Journal of Medicine, 2019, 380, 2180-2181.	13.9	5
50	Veliparib: a new therapeutic option in ovarian cancer?. Future Oncology, 2019, 15, 1975-1987.	1.1	9
51	Improvement of Metastatic Colorectal Cancer Patient Survival: Single Institution Experience. Cancers, 2019, 11, 369.	1.7	4
52	Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine. Cancers, 2019, 11, 519.	1.7	21
53	Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients. Cancers, 2019, 11, 454.	1.7	4
54	Met inhibition revokes IFNÎ³-induction of PD-1 ligands in MET-amplified tumours. British Journal of Cancer, 2019, 120, 527-536.	2.9	34

#	Article	IF	Citations
55	TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. Journal of Ovarian Research, 2019, 12, 17.	1.3	20
56	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. Oncologist, 2019, 24, 385-393.	1.9	23
57	Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. Cancers, 2019, 11, 1820.	1.7	57
58	Effectiveness of dabrafenib in the treatment of patients with BRAF V600â€“mutated metastatic melanoma in a Named Patient Program. Melanoma Research, 2019, 29, 527-532.	0.6	6
59	â€œShades of Grayâ€•in pancreatic ductal adenocarcinoma: Reappraisals on resectability criteria. Critical Reviews in Oncology/Hematology, 2019, 133, 17-24.	2.0	3
60	Quality-of-life (QoL) assessment and reporting in prostate cancer: A systematic review of phase III trials published between 2012 and 2016.. Journal of Clinical Oncology, 2019, 37, 219-219.	0.8	3
61	Emerging molecular target antagonists for the treatment of biliary tract cancer. Expert Opinion on Emerging Drugs, 2018, 23, 63-75.	1.0	14
62	Bone metastases in biliary cancers: A multicenter retrospective survey. Journal of Bone Oncology, 2018, 12, 33-37.	1.0	5
63	BRAF and MEK Inhibitors Increase PD-1-Positive Melanoma Cells Leading to a Potential Lymphocyte-Independent Synergism with Antiâ€“PD-1 Antibody. Clinical Cancer Research, 2018, 24, 3377-3385.	3.2	31
64	CD44v6 as innovative sarcoma target for CAR-redirected CIK cells. OncoImmunology, 2018, 7, e1423167.	2.1	38
65	Fluoropyrimidine-induced cardiotoxicity. Critical Reviews in Oncology/Hematology, 2018, 124, 1-10.	2.0	44
66	Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. Future Oncology, 2018, 14, 443-448.	1.1	6
67	Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2018, 19, 521-536.	5.1	486
68	Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: AÂModel From Lung Cancer. Clinical Lung Cancer, 2018, 19, 191-198.	1.1	5
69	BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report. Melanoma Research, 2018, 28, 143-146.	0.6	4
70	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repairâ€“Deficient/Microsatellite Instabilityâ€“High Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2018, 36, 773-779.	0.8	1,525
71	PARP Inhibitors in Ovarian Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 392-410.	0.8	102
72	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016. Annals of Oncology, 2018, 29, 2288-2295.	0.6	57

#	Article	IF	Citations
73	Next generation immune-checkpoints for cancer therapy. Journal of Thoracic Disease, 2018, 10, S1581-S1601.	0.6	50
74	Rationale for the use of metronomic chemotherapy in gastrointestinal cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 1451-1463.	0.9	5
75	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncology, The, 2018, 19, 1360-1371.	5.1	61
76	A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience. Journal of Ovarian Research, 2018, 11, 42.	1.3	21
77	Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. BMC Genomics, 2018, 19, 440.	1.2	13
78	Survivin-peptide vaccination elicits immune response after allogeneic nonmyeloablative transplantation: a safe strategy to enhance the graft versus tumor effect. Immunotherapy, 2018, 10, 753-767.	1.0	0
79	Selfâ€evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. Cancer Medicine, 2018, 7, 4339-4344.	1.3	29
80	Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy.. OncoImmunology, 2018, 7, e1465161.	2.1	20
81	Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. PLoS ONE, 2018, 13, e0191593.	1.1	12
82	Improvement of metastatic colorectal cancer patient survival: Single institution experience.. Journal of Clinical Oncology, 2018, 36, e15633-e15633.	0.8	0
83	Role of interferon in melanoma: old hopes and new perspectives. Expert Opinion on Biological Therapy, 2017, 17, 475-483.	1.4	21
84	Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour. European Journal of Cancer, 2017, 78, 122-132.	1.3	28
85	Frontâ€line window therapy with cisplatin in patients with primary disseminated Ewing sarcoma: A study by the Associazione Italiana di Ematologia ed Oncologia Pediatrica and Italian Sarcoma Group. Pediatric Blood and Cancer, 2017, 64, e26650.	0.8	1
86	Post-Transplant Cyclophosphamide and Tacrolimusâ€“Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Biology of Blood and Marrow Transplantation, 2017, 23, 459-466.	2.0	50
87	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	1.3	25
88	Treating breast cancer with cell-based approaches: an overview. Expert Opinion on Biological Therapy, 2017, 17, 1255-1264.	1.4	4
89	Olaratumab: PDGFR-Î± inhibition as a novel tool in the treatment of advanced soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 2017, 118, 1-6.	2.0	16
90	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	1.3	40

#	Article	IF	Citations
91	Alphaâ€“fetoprotein elevation in NUT midline carcinoma: a case report. BMC Cancer, 2017, 17, 266.	1.1	13
92	PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models. Molecular Cancer, 2017, 16, 86.	7.9	49
93	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. Clinical Cancer Research, 2017, 23, 2277-2288.	3.2	34
94	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. Therapeutic Advances in Medical Oncology, 2017, 9, 731-739.	1.4	20
95	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	0.8	89
96	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. Molecular Medicine, 2017, 23, 235-246.	1.9	9
97	Androgen receptor status predicts development of brain metastases in ovarian cancers. Oncotarget, 2017, 8, 41143-41153.	0.8	13
98	Treatment of metastatic melanoma: a multidisciplinary approach. Italian Journal of Dermatology and Venereology, 2017, 152, 241-261.	0.1	4
99	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. International Journal of Molecular Sciences, 2016, 17, 1169.	1.8	53
100	Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wildâ€type <scp>KRAS</scp> advanced biliary tract cancer: A randomized phase 2 trial (<scp>V</scp>ectiâ€«<scp>BIL</scp> study). Cancer, 2016, 122, 574-581.	2.0	121
101	Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. BMC Cancer, 2016, 16, 90.	1.1	35
102	Adoptive immunotherapy against ovarian cancer. Journal of Ovarian Research, 2016, 9, 30.	1.3	33
103	Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report. BMC Cancer, 2016, 16, 793.	1.1	8
104	Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity. Journal of Translational Medicine, 2016, 14, 119.	1.8	18
105	Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. JAMA Oncology, 2016, 2, 445.	3.4	55
106	Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient. Tumor Biology, 2016, 37, 4041-4052.	0.8	31
107	Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. Oncotarget, 2016, 7, 52354-52363.	0.8	14
108	Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget, 2016, 7, 86766-86780.	0.8	10

#	Article	IF	Citations
109	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 26181-26191.	0.8	15
110	Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen. Oncotarget, 2016, 7, 37680-37692.	0.8	37
111	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiology International, 2015, 32, 1359-1366.	0.9	1
112	Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncology, The, 2015, 16, 98-107.	5.1	270
113	Adoptive immunotherapy against sarcomas. Expert Opinion on Biological Therapy, 2015, 15, 517-528.	1.4	11
114	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. Gynecologic Oncology, 2015, 138, 627-633.	0.6	43
115	Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. Journal of Translational Medicine, 2015, 13, O1.	1.8	2
116	The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma. BMC Cancer, 2015, 15, 374.	1.1	24
117	A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. Breast Journal, 2015, 21, 241-245.	0.4	12
118	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opinion on Biological Therapy, 2015, 15, 1491-1500.	1.4	6
119	Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy, 2015, 7, 999-1010.	1.0	26
120	Recent advances in the development of breast cancer vaccines. Breast Cancer: Targets and Therapy, 2014, 6, 159.	1.0	18
121	Activity of cytokine-induced killer cells against bone and soft tissue sarcoma. OncoImmunology, 2014, 3, e28269.	2.1	3
122	Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models. BMC Cancer, 2014, 14, 918.	1.1	8
123	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology, 2014, 25, 1750-1755.	0.6	164
124	Anticoagulation for Central Venous Catheters in Patients with Cancer. New England Journal of Medicine, 2014, 371, 1362-1363.	13.9	23
125	Screening for the FIGâ€ROS1 fusion in biliary tract carcinomas by nested PCR. Genes Chromosomes and Cancer, 2014, 53, 1033-1040.	1.5	23
126	Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. British Journal of Cancer, 2014, 110, 2165-2169.	2.9	69

#	Article	IF	Citations
127	Potential biomarkers of longâ€term benefit from singleâ€agent trastuzumab or lapatinib in HER2â€positive metastatic breast cancer. Molecular Oncology, 2014, 8, 20-26.	2.1	37
128	Cytokine-Induced Killer Cells Eradicate Bone and Soft-Tissue Sarcomas. Cancer Research, 2014, 74, 119-129.	0.4	67
129	Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy. Breast, 2014, 23, 44-49.	0.9	25
130	Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkinâ€™s lymphoma: a case report and review of the literature. BMC Research Notes, 2014, 7, 529.	0.6	24
131	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. Journal of Experimental and Clinical Cancer Research, 2014, 33, 30.	3.5	97
132	Immunotherapy of cancer stem cells in solid tumors: initial findings and future prospective. Expert Opinion on Biological Therapy, 2014, 14, 1259-1270.	1.4	18
133	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. Journal of Translational Medicine, 2014, 12, 116.	1.8	149
134	Metastatic breast cancer subtypes and central nervous system metastases. Breast, 2014, 23, 623-628.	0.9	95
135	Potentially resectable metastatic colorectal cancer: An individualized approach to conversion therapy. Critical Reviews in Oncology/Hematology, 2014, 92, 218-226.	2.0	11
136	Genetically Redirected T Lymphocytes for Adoptive Immunotherapy of Solid Tumors. Current Gene Therapy, 2014, 14, 52-62.	0.9	20
137	Ex Vivo-Activated MHC-Unrestricted Immune Effectors for Cancer Adoptive Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 211-222.	0.9	4
138	Induction gemcitabine and oxaliplatin therapy followed by a twiceâ€weekly infusion of gemcitabine and concurrent externalâ€beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer. Cancer, 2013, 119, 277-284.	2.0	72
139	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	2.0	26
140	Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Medical Oncology, 2013, 30, 581.	1.2	11
141	Duration of trastuzumab for HER2-positive breast cancer. Lancet Oncology, The, 2013, 14, 678-679.	5.1	3
142	Biliary tract carcinomas: From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology, 2013, 85, 136-148.	2.0	39
143	The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 Upregulation in Osteosarcoma Preclinical Models. Clinical Cancer Research, 2013, 19, 2117-2131.	3.2	96
144	What can we learn from the ZOOM trial? â€“ Authors' reply. Lancet Oncology, The, 2013, 14, e388-e390.	5.1	1

#	Article	IF	Citations
145	Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncology, The, 2013, 14, 663-670.	5.1	165
146	Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP). , 2013, 1, .		4
147	Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Annals of Oncology, 2013, 24, 1740-1748.	0.6	74
148	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. Bone Marrow Transplantation, 2013, 48, 414-418.	1.3	16
149	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. Clinical Cancer Research, 2013, 19, 4347-4358.	3.2	81
150	Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.. Journal of Clinical Oncology, 2013, 31, 9070-9070.	0.8	9
151	Targeted agents: how can we improve the outcome in biliary tract cancer?. Hepatobiliary Surgery and Nutrition, 2013, 2, 31-3.	0.7	4
152	The Role of Lung Metastasis Resection in Improving Outcome of Colorectal Cancer Patients: Results From a Large Retrospective Study. Oncologist, 2012, 17, 1430-1438.	1.9	65
153	Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas. Molecular Cancer Therapeutics, 2012, 11, 1528-1538.	1.9	14
154	Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. Oncologist, 2012, 17, 1418-1425.	1.9	79
155	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	0.6	108
156	Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2012, 13, 2143-2156.	0.9	6
157	Prolonged Disease Stability With Trabectedin in a Heavily Pretreated Elderly Patient With Metastatic Leiomyosarcoma of the Thigh and Renal Failure: A Case Report and Review of the Literature. Oncology Research, 2012, 20, 483-490.	0.6	5
158	Imaging as a potential tool for subtyping breast cancer. Imaging in Medicine, 2012, 4, 577-579.	0.0	0
159	Gingival metastasis of a radiotherapy-induced breast angiosarcoma. Anti-Cancer Drugs, 2012, 23, 1112-1117.	0.7	6
160	Ex Vivo Allogeneic Stimulation Significantly Improves Expansion of Cytokine-Induced Killer Cells Without Increasing Their Alloreactivity Across HLA Barriers. Journal of Immunotherapy, 2012, 35, 579-586.	1.2	21
161	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet, The, 2012, 379, 1879-1886.	6.3	1,752
162	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1600-1607.	2.0	25

#	Article	IF	Citations
163	Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. Annals of Surgical Oncology, 2012, 19, 3755-3761.	0.7	20
164	Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opinion on Biological Therapy, 2012, 12, 673-684.	1.4	124
165	A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy. Oncology Letters, 2012, 3, 819-824.	0.8	12
166	Potential of afatinib in the treatment of patients with HER2-positive breast cancer. Breast Cancer: Targets and Therapy, 2012, 4, 131.	1.0	12
167	A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Annals of Oncology, 2012, 23, 508-516.	0.6	296
168	153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Annals of Oncology, 2012, 23, 1899-1905.	0.6	25
169	In vivo characterisation of soft tissue tumours by 1.5-T proton MR spectroscopy. European Radiology, 2012, 22, 1131-1139.	2.3	14
170	Correlations between diffusion-weighted imaging and breast cancer biomarkers. European Radiology, 2012, 22, 1519-1528.	2.3	206
171	Hormoneâ€receptor expression and activity of trastuzumab with chemotherapy in HER2â€positive advanced breast cancer patients. Cancer, 2012, 118, 17-26.	2.0	58
172	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. Journal of Clinical Oncology, 2012, 30, 10009-10009.	0.8	4
173	Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).. Journal of Clinical Oncology, 2012, 30, e15073-e15073.	0.8	0
174	Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34+ cells and T lymphocytes: Implications for the use of low viral doses and large-size vectors. Journal of Biotechnology, 2011, 156, 218-226.	1.9	14
175	Trastuzumab in the adjuvant setting: a practical review. Therapy: Open Access in Clinical Medicine, 2011, 8, 161-177.	0.2	0
176	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood, 2011, 117, 6721-6727.	0.6	113
177	Enhanced c-Met activity promotes G-CSFâ€“induced mobilization of hematopoietic progenitor cells via ROS signaling. Blood, 2011, 117, 419-428.	0.6	114
178	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. British Journal of Cancer, 2011, 104, 1686-1690.	2.9	65
179	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	0.6	42
180	HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. Breast Cancer Research and Treatment, 2011, 130, 29-40.	1.1	47

#	Article	IF	Citations
181	Risk evaluation, prophylaxis, and treatment of tumor lysis syndrome: Consensus of an Italian expert panel. Advances in Therapy, 2011, 28, 684-697.	1.3	18
182	Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer, 2011, 11, 31.	1.1	86
183	A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing plateletâ€derived growth factor receptorâ€Î± or â€Î². Cancer, 2011, 117, 826-831.	2.0	42
184	Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. Expert Opinion on Pharmacotherapy, 2011, 12, 549-565.	0.9	9
185	Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. Oncologist, 2011, 16, 534-536.	1.9	1
186	Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks. Expert Opinion on Biological Therapy, 2011, 11, 655-666.	1.4	3
187	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised â€˜GISCADâ€™ trial. Annals of Oncology, 2011, 22, 1236-1242.	0.6	98
188	Complete Resolution of Life-Threatening Bleomycin-Induced Pneumonitis After Treatment With Imatinib Mesylate in a Patient With Hodgkin's Lymphoma: Hope for Severe Chemotherapy-Induced Toxicity?. Journal of Clinical Oncology, 2011, 29, e691-e693.	0.8	38
189	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	0.9	61
190	Preoperation Chemotherapy. Updates in Surgery Series, 2011, , 75-100.	0.0	0
191	Effect of AZD0530 (saracatinib) on biliary cancer cell motility and invasion.. Journal of Clinical Oncology, 2011, 29, 231-231.	0.8	1
192	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer, 2010, 10, 28.	1.1	13
193	Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer, 2010, 10, 631.	1.1	149
194	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. European Urology, 2010, 58, 906-911.	0.9	55
195	Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. British Journal of Surgery, 2010, 97, 1354-1362.	0.1	74
196	Role of trastuzumab in the management of HER2-positive metastatic breast cancer. Breast Cancer: Targets and Therapy, 2010, 2, 93.	1.0	8
197	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. Oncologist, 2010, 15, 665-672.	1.9	8
198	Anthracycline-based adjuvant chemotherapy in breast cancer. Lancet, The, 2010, 375, 1871.	6.3	0

#	Article	IF	Citations
199	Trastuzumab Beyond Disease Progression: Case Closed?. Journal of Clinical Oncology, 2009, 27, e121-e122.	0.8	5
200	Reply to A. SÃ¡nchez-MuÃ±oz et al. Journal of Clinical Oncology, 2009, 27, e257-e258.	0.8	0
201	Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy. Endocrine-Related Cancer, 2009, 16, 1091-1102.	1.6	29
202	Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer. Journal of Clinical Oncology, 2009, 27, 2566-2567.	0.8	10
203	Translocation-Related Sarcomas. Seminars in Oncology, 2009, 36, 312-323.	0.8	67
204	Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed highâ€risk osteosarcoma patients. Cancer, 2009, 115, 2980-2987.	2.0	50
205	Efficient Transcriptional Targeting of Human Hematopoietic Stem Cells and Blood Cell Lineages by Lentiviral Vectors Containing the Regulatory Element of the Wiskott-Aldrich Syndrome Gene. Stem Cells, 2009, 27, 2815-2823.	1.4	11
206	Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opinion on Biological Therapy, 2009, 9, 831-840.	1.4	48
207	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The â€˜GISCAD-alternating scheduleâ€™ study findings. European Journal of Cancer, 2009, 45, 65-73.	1.3	48
208	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
209	Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Molecular Cancer, 2009, 8, 118.	7.9	159
210	An Acute Hepatitis Resembling Autoimmune Hepatitis Occurring During Imatinib Therapy in a Gastrointestinal Stromal Tumor Patient. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 640-641.	0.6	21
211	Sustained Long-Term Engraftment and Transgene Expression of Peripheral Blood CD34+Cells Transduced with Third-Generation Lentiviral Vectors. Stem Cells, 2008, 26, 1620-1627.	1.4	8
212	Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplantation, 2008, 41, S131-S134.	1.3	28
213	MYELOFIBROSIS AND PROSTAGLANDINS: EFFECT OF PROSTAGLANDIN E1 ON COLONY-FORMING CELLS (CFU-GM). British Journal of Haematology, 2008, 48, 167-169.	1.2	4
214	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer, 2008, 8, 209.	1.1	8
215	Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. Clinical Breast Cancer, 2008, 8, 436-442.	1.1	25
216	Refreezing of cord blood hematopoietic stem cells for allogenic transplantation: in vitro and in vivo validation of a clinical phase I/II protocol in European and Italian Good Manufacturing Practice conditions. Experimental Hematology, 2008, 36, 235-243.	0.2	16

#	Article	IF	Citations
217	Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. International Immunology, 2008, 20, 841-848.	1.8	106
218	Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. Journal of Clinical Oncology, 2008, 26, 2052-2053.	0.8	13
219	Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology, 2008, 5, 256-267.	4.3	78
220	Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab. Anti-Cancer Drugs, 2008, 19, 689-696.	0.7	7
221	Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis. Acta OncolÃ³gica, 2007, 46, 664-668.	0.8	46
222	Does addition of lapatinib to capecitabine improve outcome in women with refractory breast cancer?. Nature Clinical Practice Oncology, 2007, 4, 398-399.	4.3	2
223	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. New England Journal of Medicine, 2007, 356, 1110-1120.	13.9	479
224	Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opinion on Biological Therapy, 2007, 7, 257-268.	1.4	96
225	Patients with advanced stage breast carcinoma immunoreactive to biotinylated HerceptinÂ® are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Annals of Oncology, 2007, 18, 1963-1968.	0.6	12
226	Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma. Journal of Clinical Oncology, 2007, 25, 1145-1145.	0.8	6
227	Response to melphalan in up-front investigational window therapy for patients with metastatic Ewingâ€™s family tumours. European Journal of Cancer, 2007, 43, 885-890.	1.3	7
228	Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. Expert Opinion on Pharmacotherapy, 2007, 8, 1179-1188.	0.9	0
229	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Annals of Oncology, 2007, 18, 977-984.	0.6	498
230	Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer. European Radiology, 2007, 17, 1490-1497.	2.3	56
231	Tumor Cell Purging by Ex Vivo Expansion of Hemopoietic Stem Cells from Breast Cancer Patients Combined with Targeting ErbB Receptors. Biology of Blood and Marrow Transplantation, 2006, 12, 68-74.	2.0	5
232	Diagnostic accuracy of portal-phase CT and MRI with mangafodipir trisodium in detecting liver metastases from colorectal carcinoma. Clinical Radiology, 2006, 61, 338-347.	0.5	42
233	Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood, 2006, 107, 3795-3803.	0.6	46
234	Serial Transplantations in Nonobese Diabetic/Severe Combined Immunodeficiency Mice of Transduced Human CD34+Cord Blood Cells: Efficient Oncoretroviral Gene Transfer and Ex Vivo Expansion Under Serum-Free Conditions. Stem Cells, 2006, 24, 1201-1212.	1.4	8

#	Article	IF	Citations
235	Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival. Annals of Surgical Oncology, 2006, 13, 1201-1208.	0.7	130
236	Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach. Diseases of the Colon and Rectum, 2006, 49, 1596-1601.	0.7	24
237	Neoadjuvant chemotherapy and resection for initially irresectable colorectal liver metastases. British Journal of Surgery, 2006, 93, 1001-1006.	0.1	71
238	Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. Journal of Cellular Biochemistry, 2006, 97, 744-754.	1.2	289
239	Concurrent Radiotherapy Does Not Affect Adjuvant CMF Delivery but is Associated with Increased Toxicity in Women with Early Breast Cancer. Journal of Chemotherapy, 2006, 18, 90-97.	0.7	5
240	Trastuzumab Treatment in Breast Cancer. New England Journal of Medicine, 2006, 354, 2186-2186.	13.9	11
241	Jaw complications in breast and prostate cancer patients treated with zoledronic acid. Acta OncolÃ³gica, 2006, 45, 216-217.	0.8	21
242	Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma. Clinical Cancer Research, 2006, 12, 1680-1685.	3.2	151
243	Outcome of Patients with HER2â€Positive Advanced Breast Cancer Progressing During Trastuzumabâ€Based Therapy. Oncologist, 2006, 11, 318-324.	1.9	116
244	High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults. Annals of Oncology, 2006, 17, 1479-1488.	0.6	39
245	The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. British Journal of Cancer, 2006, 95, 13-20.	2.9	35
246	Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer. European Radiology, 2005, 15, 1224-1233.	2.3	34
247	TGFÎ± expression impairs Trastuzumab-induced HER2 downregulation. Oncogene, 2005, 24, 3002-3010.	2.6	113
248	Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study. Experimental Hematology, 2005, 33, 1371-1387.	0.2	9
249	The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer, 2005, 103, 1314-1315.	2.0	5
250	Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 3871-3872.	0.8	30
251	Continuation of Trastuzumab Beyond Disease Progression. Journal of Clinical Oncology, 2005, 23, 2866-2868.	0.8	20
252	Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer. Oncology, 2005, 68, 493-499.	0.9	44

#	Article	IF	Citations
253	A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. British Journal of Cancer, 2005, 92, 1261-1267.	2.9	27
254	Controversies in breast cancer: adjuvant and neoadjuvant therapy. Expert Opinion on Pharmacotherapy, 2005, 6, 1055-1072.	0.9	5
255	Allogeneic Hemopoietic Stem Cell Transplantation in Solid Tumors. Transplantation Proceedings, 2005, 37, 2664-2666.	0.3	8
256	Incorporating Trastuzumab into the Neoadjuvant Treatment of HER2-Overexpressing Breast Cancer. Clinical Breast Cancer, 2005, 6, 77-80.	1.1	21
257	Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clinical Cancer Research, 2005, 11, 490-7.	3.2	83
258	Vasculogenic potential of long term repopulating cord blood progenitors. FASEB Journal, 2004, 18, 1273-1275.	0.2	20
259	A Phase II Study of Three-Weekly Docetaxel and Weekly Trastuzumab in HER2-Overexpressing Advanced Breast Cancer. Oncology, 2004, 66, 38-45.	0.9	48
260	Trastuzumab-based combination therapy for breast cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 81-96.	0.9	43
261	Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy. Acta Radiologica, 2004, 45, 71-74.	0.5	23
262	Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging. Breast Cancer Research and Treatment, 2004, 83, 67-76.	1.1	225
263	Fast But Durable Megakaryocyte Repopulation and Platelet Production in NOD/SCID Mice Transplanted with Ex-Vivo Expanded Human Cord Blood CD34+ Cells. Stem Cells, 2004, 22, 135-143.	1.4	33
264	HER2 and Central Nervous System Metastasis in Patients with Breast Cancer. Clinical Breast Cancer, 2004, 5, 232-234.	1.1	10
265	A Large-Scale Study of Bone Marrow Involvement in Patients with Hodgkin's Lymphoma. Clinical Lymphoma and Myeloma, 2004, 5, 50-55.	2.1	34
266	Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication. Blood, 2004, 103, 4440-4448.	0.6	81
267	Tumor progression in osteosarcoma (OS): Role of the chemokine receptor CXCR4 and of its ligand stromal-cell derived factor 1 (SDF-1). Journal of Clinical Oncology, 2004, 22, 9021-9021.	0.8	1
268	Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability. Breast Cancer Research and Treatment, 2003, 82, 185-190.	1.1	9
269	Ex vivo expansion of human adult stem cells capable of primary and secondary hemopoietic reconstitution. Experimental Hematology, 2003, 31, 261-270.	0.2	85
270	ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells. British Journal of Cancer, 2003, 88, 396-400.	2.9	19

#	Article	IF	Citations
271	Expression of the c-ErbB-2/HER2 proto-oncogene in normal hematopoietic cells. Journal of Leukocyte Biology, 2003, 74, 593-601.	1.5	17
272	Safety and Activity of Docetaxel and Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 95-97.	0.6	28
273	Gastrointestinal Stromal Tumors: Should They Be Treated with the Same Systemic Chemotherapy as Other Soft Tissue Sarcomas?. Oncology, 2003, 64, 186-188.	0.9	15
274	Regression of metastatic osteosarcoma following non-myeloablative stem cell transplantation. A case report. Haematologica, 2003, 88, ECR16.	1.7	5
275	High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study. Journal of Clinical Oncology, 2002, 20, 2150-2156.	0.8	137
276	Role of different medium and growth factors on placental blood stem cell expansion: an in vitro and in vivo study. Bone Marrow Transplantation, 2002, 29, 443-448.	1.3	11
277	Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Blood, 2002, 100, 4391-4400.	0.6	84
278	MEKâ€“ERK pathway is expressed but not activated in high proliferating, self-renewing cord blood hematopoietic progenitors. The Hematology Journal, 2002, 3, 105-113.	2.0	8
279	Detection of breast cancer cell contamination in leukapheresis product by real-time quantitative polymerase chain reaction. Bone Marrow Transplantation, 2001, 27, 517-523.	1.3	19
280	Different growth factor requirements for the ex vivo amplification of transplantable human cord blood cells in a NOD/SCID mouse model. Journal of Biological Regulators and Homeostatic Agents, 2001, 15, 38-48.	0.7	19
281	Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica, 2001, 86, 1099-100.	1.7	231
282	Short term treatment withEscheria coli recombinant human granulocyte-macrophage-colony stimulating factor prior to chemotherapy for Hodgkin disease. , 2000, 88, 454-460.		12
283	The involvement of human-nuc gene in polyploidization of K562 cell line. Experimental Hematology, 2000, 28, 1432-1440.	0.2	12
284	Ex vivo expansion of megakaryocytes. Transfusion Science, 2000, 22, 107-110.	0.6	5
285	Negative Influence of IL3 on the Expansion of Human Cord BloodIn VivoLong-Term Repopulating Stem Cells. Journal of Hematotherapy and Stem Cell Research, 2000, 9, 945-956.	1.8	28
286	High-Dose Chemotherapy with Hematopoietic Stem-Cell Transplantation for Breast Cancer: Current Status, Future Trends. Clinical Breast Cancer, 2000, 1, 197-209.	1.1	7
287	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. Blood, 1999, 93, 3736-3749.	0.6	296
288	Engraftment in Nonobese Diabetic Severe Combined Immunodeficient Mice of Human CD34+ Cord Blood Cells After Ex Vivo Expansion: Evidence for the Amplification and Self-Renewal of Repopulating Stem Cells. Blood, 1999, 93, 3736-3749.	0.6	12

#	Article	IF	Citations
289	Role of Hematopoietic Growth Factors on the ex Vivo Expansion of Primitive Cord Blood Stem Cells. , 1999, , 39-50.		0
290	Ex Vivo Expansion of Cord Blood Progenitors. Vox Sanguinis, 1998, 74, 457-462.	0.7	14
291	Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. Leukemia, 1998, 12, 718-727.	3.3	114
292	The role of c‐Mpl ligands in the expansion of cord blood hematopoietic progenitors. Stem Cells, 1998, 16, 243-248.	1.4	12
293	Ex vivo expansion of hematopoietic cells and their clinical use. Haematologica, 1998, 83, 824-48.	1.7	14
294	Activation of JAK2 in Human Vascular Endothelial Cells by Granulocyte-Macrophage Colony-Stimulating Factor. Blood, 1997, 89, 863-872.	0.6	42
295	Extensive Amplification and Self-Renewal of Human Primitive Hematopoietic Stem Cells From Cord Blood. Blood, 1997, 89, 2644-2653.	0.6	434
296	Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl. Leukemia, 1997, 11, 531-540.	3.3	15
297	Flow cytometric detection and quantitative analysis of the GM-CSF receptor in human granulocytes and comparison with the radioligand binding assay. , 1996, 24, 374-381.		11
298	The effects of human FLT3 ligand on in vitro human megakaryocytopoiesis. Experimental Hematology, 1996, 24, 340-6.	0.2	24
299	Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography. European Journal of Clinical Investigation, 1995, 25, 68-70.	1.7	29
300	Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood, 1995, 86, 4105-4114.	0.6	71
301	A comparison of two GM-CSF schedules to counteract the granulo-monocytopenia of carboplatin-etoposide chemotherapy. European Journal of Cancer, 1995, 31, 46-49.	1.3	6
302	Platelet activating factor produced in vitro by Kaposi's sarcoma cells induces and sustains in vivo angiogenesis.. Journal of Clinical Investigation, 1995, 96, 940-952.	3.9	98
303	Involvement of a serine protease in the synthesis of platelet-activating factor by endothelial cells stimulated by tumor necrosis factor-Î± or interleukin-1Î±. European Journal of Immunology, 1994, 24, 3131-3139.	1.6	30
304	GM-CSF and dose escalation of chemotherapy. Annals of Oncology, 1994, 5, 663.	0.6	0
305	Human endothelial cells are targets for platelet-activating factor (PAF). Activation of alpha and beta protein kinase C isozymes in endothelial cells stimulated by PAF. Journal of Biological Chemistry, 1994, 269, 2877-86.	1.6	63
306	Rationale for the use of granulocyte-macrophage colony-stimulating factor in oncology. Seminars in Oncology, 1994, 21, 5-9.	0.8	57

#	Article	IF	Citations
307	Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs. Cancer, 1993, 72, 2970-2973.	2.0	29
308	Transmission of Hepatitis C via Blood Splash into Conjunctiva. Scandinavian Journal of Infectious Diseases, 1993, 25, 270-271.	1.5	145
309	Granulocyte-Macrophage colony stimulating factor and interleukin 3: Target cells and kinetics of response in vivo. Stem Cells, 1993, 11, 83-87.	1.4	12
310	Haemopoietic growth factors in oncology. Pharmacological Research, 1992, 26, 80-81.	3.1	0
311	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia. Cancer Genetics and Cytogenetics, 1991, 52, 63-69.	1.0	6
312	Effect of recombinant human IL-3 on the mitotic index and karyotype of hemopoietic cells. Cancer Genetics and Cytogenetics, 1991, 55, 235-241.	1.0	4
313	In vivo effect of human granulocyte-macrophage colony-stimulating factor on megakaryocytopoiesis. Blood, 1991, 77, 1191-1194.	0.6	48
314	Essential thrombocythemia: Impaired regulation of megakaryocyte progenitors. International Journal of Cell Cloning, 1991, 9, 43-56.	1.6	23
315	Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. British Journal of Haematology, 1991, 79, 451-456.	1.2	18
316	In vivo priming of human normal neutrophils by granulocyte-macrophage colony stimulating factor: effect on the production of platelet activating factor. British Journal of Haematology, 1990, 75, 333-339.	1.2	14
317	Human GM-CSF in vivo: Identification of the target cells and of their kinetics of response. International Journal of Cell Cloning, 1990, 8, 283-292.	1.6	5
318	Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) Reduces Pancytopenia After Rescue Therapy in a Patient with Hodgkin's Lymphoma. Leukemia and Lymphoma, 1990, 3, 61-66.	0.6	0
319	Effect of Hemopoietic Growth Factors on the Proliferation of Acute Myeloid and Lymphoid Leukemias. Leukemia and Lymphoma, 1990, 2, 207-214.	0.6	3
320	GM-CSF: intravenous versus subcutaneous treatment. Leukemia, 1990, 4, 523.	3.3	5
321	Granulocyte- and granulocyteâ€“ macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature, 1989, 337, 471-473.	13.7	640
322	Kinetics of human hemopoietic cells after in vivo administration of granulocyte-macrophage colony-stimulating factor.. Journal of Clinical Investigation, 1989, 83, 551-557.	3.9	132
323	Interaction of transforming growth factor-beta 1 with hemopoietic growth factors in the regulation of human normal and leukemic myelopoiesis. Experimental Hematology, 1989, 17, 296-9.	0.2	20
324	Effect of interferon-gamma on hla class II antigen expression and sensitivity to prostaglandin E1 by normal and leukemic myeloid progenitors. Leukemia Research, 1988, 12, 299-303.	0.4	0

#	Article	IF	Citations
325	Autologous Bone Marrow Transplantation in Acute Lymphoblastic Leukemiaâ€"Mafosfamide Italian Study Group. Plant Systematics and Evolution Supplementum = Entwicklungsgeschichte Und Systematik Der Pflanzen Supplementum, 1988, , 89-93.	1.5	0
326	Studies on the mechanism of interleukin 1 stimulation of platelet activating factor synthesis in human endothelial cells in culture. Biochimica Et Biophysica Acta - Molecular Cell Research, 1987, 927, 43-54.	1.9	34
327	Autologous Bone Marrow Transplantation in Acute Leukemia. Acta Haematologica, 1987, 78, 190-193.	0.7	2
328	7q-and loss of a polymorphism for the met oncogene in a patient with myelofibrosis. Cytotechnology, 1987, 1, 37-40.	0.7	0
329	Expression of HLA class II determinants by normal and chronic myeloid leukemia progenitors. Leukemia Research, 1987, 11, 285-290.	0.4	6
330	Human endothelial cells are target for platelet-activating factor. I. Platelet-activating factor induces changes in cytoskeleton structures. Journal of Immunology, 1987, 139, 2439-46.	0.4	146
331	Human gamma interferon modifies C-myc expression and growth pattern of U937 cell line but not of its subclone 1937. Cell Biology International Reports, 1986, 10, 467.	0.7	1
332	Translocation of the c-myc oncogene 3â€² to the immunoglobin heavy chain enhancer in the tumor DNA from a Burkitt lymphoma. Cell Biology International Reports, 1986, 10, 148-148.	0.7	0
333	Human gamma interferon enhances release from phytohemagglutinin- stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. Blood, 1986, 68, 1339-1347.	0.6	28
334	Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cells.. Molecular and Cellular Biology, 1986, 6, 1803-1811.	1.1	60
335	Interleukin 1 stimulates platelet activating factor production in cultured human endothelial cells. Pharmacological Research Communications, 1986, 18, 133-137.	0.2	85
336	Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells.. Journal of Clinical Investigation, 1986, 77, 2027-2033.	3.9	205
337	Human gamma interferon enhances release from phytohemagglutinin-stimulated T4+ lymphocytes of activities that stimulate colony formation by granulocyte-macrophage, erythroid, and multipotential progenitor cells. Blood, 1986, 68, 1339-47.	0.6	9
338	Expression of HLA class II (DR, DQ) determinants by normal and chronic myeloid leukemia granulocyte/monocyte progenitors. Cancer Research, 1986, 46, 1783-7.	0.4	14
339	In-vitro effect of retinoic acid on normal and chronic myeloid leukemia granulopoiesis. Leukemia Research, 1985, 9, 879-883.	0.4	15
340	H2 receptor antagonists and human granulopoiesis. Experientia, 1985, 41, 375-376.	1.2	6
341	Retinoic Acid Enhances the Growth of Only One Subpopulation of Granulomonocyte Precursors. Acta Haematologica, 1984, 71, 97-99.	0.7	9
342	Differences in the in vitro growth pattern of fresh and cryopreserved granulo-monopoietic precursors. Cryobiology, 1984, 21, 486-490.	0.3	8

#	Article	IF	Citations
343	Biosynthesis and Release of Platelet-Activating Factor from Human Monocytes. International Archives of Allergy and Immunology, 1983, 70, 245-251.	0.9	57
344	Responsiveness to Prostaglandin E₁ of Different Subtypes of Normal and Pathological Committed Granulomonopoietic Precursors. Acta Haematologica, 1983, 69, 376-381.	0.7	2
345	The release of platelet-activating factor from human endothelial cells in culture. Journal of Immunology, 1983, 131, 2397-403.	0.4	333
346	Prostaglandins and myelopoiesis: Effect of prostaglandin E on normal and chronic myeloid leukemia colony forming cells (CFU-GM) subpopulations. Cell Biology International Reports, 1981, 5, 836.	0.7	1
347	Effect of lithium on normal and chronic granulocytic leukemia colony forming cells (CFU-GM). Experientia, 1981, 37, 1340-1341.	1.2	4
348	Detection of basophils growing in semisolid agar culture. Experimental Hematology, 1981, 9, 95-100.	0.2	13
349	Normal and leukaemic granulopoiesis. Haematologica, 1981, 66, 1-17.	1.7	4
350	Atypical myeloproliferative disorder associated with a 21 trisomic clone. Research in Clinic and Laboratory, 1981, 11, 111-115.	0.3	0
351	Insensitivity of chronic myeloid leukemia cells to inhibition of growth by prostaglandin E1. Cancer Research, 1980, 40, 2507-11.	0.4	39
352	The relevance of cell kinetics for optimal scheduling of 1-?-d-Arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML). Cancer Chemotherapy and Pharmacology, 1978, 1, 219-23.	1.1	13
353	Short-term effects of colcemid on the rapid axonal transport of proteins in the optic pathway of chick embryos. Experientia, 1973, 29, 1126-1127.	1.2	6
354	The development of axonal transport of proteins and glycoproteins in the optic pathway of chick embryos. Brain Research, 1973, 63, 273-284.	1.1	36